MedPath
Found 1 clinical trials|View Analysis
Sort by:

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Phase 1
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Sasanlimab Prefilled syringe
Drug: Sasanlimab
Drug: Encorafenib
Drug: Axitinib
Drug: SEA-TGT
Drug: Binimetinib
First Posted Date
2020-10-14
Last Posted Date
2024-12-17
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT04585815
Locations
🇨🇳

Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan

🇺🇸

UC San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States

and more 50 locations
© Copyright 2025. All Rights Reserved by MedPath